Yu Lei1, Jumana M Jaradat2, Adepitan Owosho2, Kehinde E Adebiyi3, Kelley S Lybrand4, Brad W Neville5, Susan Müller6, Elizabeth A Bilodeau2. 1. Department of Diagnostic Sciences, University of Pittsburgh School of Dental Medicine, Pittsburgh, PA, USA. Electronic address: leiy@upmc.edu. 2. Department of Diagnostic Sciences, University of Pittsburgh School of Dental Medicine, Pittsburgh, PA, USA. 3. Obafemi Awolowo University, Ile-Ife, Nigeria. 4. Division of Oral and Maxillofacial Surgery, Medical University of South Carolina, Charleston, SC, USA. 5. Division of Oral Pathology, Department of Stomatology, Medical University of South Carolina, Charleston, SC, USA. 6. Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Abstract
OBJECTIVE: Ameloblastic carcinoma often poses diagnostic challenges in its separation from benign ameloblastoma with atypical cytologic features or an unusual clinical course. This study aimed to determine whether SOX2 (sex determining region-Y-related high mobility group box 2), a protein expressed in the epithelial basal proliferative zone in dentigerous cysts, is a marker for ameloblastic carcinoma as well as for high-grade transformation in ameloblastic neoplasms. STUDY DESIGN: Immunoperoxidase stains were performed according to a standard protocol. Immunostains were interpreted independently by 3 pathologists, and scores were recorded based on the percentage of staining and intensity of staining in the cells of interest. RESULTS: The diffuse strong nuclear staining pattern has 86.4% specificity (19 of 22) to indicate the presence of high-grade features and has 76.9% sensitivity (10 of 13) in comparison with benign counterparts (P = .0021). Although previously shown as a marker for ameloblastic neoplasms, calretinin is weakly positive in a few cells in 50% (5 of 10) of ameloblastic carcinoma and 43% (3 of 7) of benign ameloblastic neoplasms, with little value in highlighting the high-grade change (P = .36). CONCLUSIONS: The diffuse nuclear staining pattern of SOX2 is suggestive of a high-grade process in ameloblastic neoplasms. Numerous aggregates of cells harboring dense nuclear stain should raise concern for a malignancy.
OBJECTIVE:Ameloblastic carcinoma often poses diagnostic challenges in its separation from benign ameloblastoma with atypical cytologic features or an unusual clinical course. This study aimed to determine whether SOX2 (sex determining region-Y-related high mobility group box 2), a protein expressed in the epithelial basal proliferative zone in dentigerous cysts, is a marker for ameloblastic carcinoma as well as for high-grade transformation in ameloblastic neoplasms. STUDY DESIGN: Immunoperoxidase stains were performed according to a standard protocol. Immunostains were interpreted independently by 3 pathologists, and scores were recorded based on the percentage of staining and intensity of staining in the cells of interest. RESULTS: The diffuse strong nuclear staining pattern has 86.4% specificity (19 of 22) to indicate the presence of high-grade features and has 76.9% sensitivity (10 of 13) in comparison with benign counterparts (P = .0021). Although previously shown as a marker for ameloblastic neoplasms, calretinin is weakly positive in a few cells in 50% (5 of 10) of ameloblastic carcinoma and 43% (3 of 7) of benign ameloblastic neoplasms, with little value in highlighting the high-grade change (P = .36). CONCLUSIONS: The diffuse nuclear staining pattern of SOX2 is suggestive of a high-grade process in ameloblastic neoplasms. Numerous aggregates of cells harboring dense nuclear stain should raise concern for a malignancy.
Authors: Eduardo Alonso Cruz Monroy; Pedro Paulo de Andrade Santos; Maria Luiza Diniz de Sousa Lopes; Adalberto Mosqueda-Taylor; Leão Pereira Pinto; Lélia Batista de Souza Journal: Histochem Cell Biol Date: 2018-07-03 Impact factor: 4.304
Authors: Yee Sun Tan; Kanokwan Sansanaphongpricha; Yuying Xie; Christopher R Donnelly; Xiaobo Luo; Blake R Heath; Xinyi Zhao; Emily Bellile; Hongxiang Hu; Hongwei Chen; Peter J Polverini; Qianming Chen; Simon Young; Thomas E Carey; Jacques E Nör; Robert L Ferris; Gregory T Wolf; Duxin Sun; Yu L Lei Journal: Clin Cancer Res Date: 2018-05-16 Impact factor: 13.801